OTC Markets OTCPK USD

Virpax Pharmaceuticals, Inc. (VRPX)

0.2432

-0.0268

(-9.93%)

At close: May 7 at 3:23:02 PM EDT

Virpax Pharmaceuticals Announces Reverse Stock Split

BERWYN, Pa., March 19, 2025--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company") a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split ("reverse split") of its common stock, par value $0.0001 per share ("Common Stock"), that will become effective at 12:01 a.m. Eastern Time on Ma

Business Wire last month

VRPX
-9.93%
Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND

BERWYN, Penn., March 18, 2025--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced positive results from a beagle dog dose range finding ("DRF") study. Probudur is the company’s long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate

Business Wire last month

VRPX
-9.93%
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine

BERWYN, Pa., March 07, 2025--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is looking to use Molecular Envelope Technology (MET) or a similar technology to deliver a mRNA COVID vaccine. Virpax currently uses its MET for Envelta (NES100) and NobrXiol (VRP324).

Business Wire last month

VRPX
-9.93%
Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS

BERWYN, Pa., March 05, 2025--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is pleased to announce its NES100 dose range finding toxicity study will be presented at The Society of Toxicology (SOT) 64th annual meeting and Tox Expo taking place March 16-20th in Orlando, FL. This is a pre

Business Wire 2 months ago

VRPX
-9.93%
Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology

BERWYN, Pa., February 27, 2025--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, would like to congratulate Nanomerics on completing a human study using the Molecular Envelope Technology (MET) and showing no moderate to severe adverse events. Virpax uses MET in its Envelta (NES100) and N

Business Wire 2 months ago

VRPX
-9.93%
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate

On Friday, Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) completed the full study following the initial Probudur pilot study performed by the U.S. Army Institute of Surgical Research (USAISR) under an existing Cooperative Research and Development Agreement (CRADA). The USAISR is the U.S. Department of Defense’s premier research organization for developing solutions for trauma and critical care challenges in combat casualties. The study was designed to determine if Probudur reduces pain behaviors in

Benzinga 2 months ago

VRPX
-9.93%
Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study

BERWYN, Pa., February 13, 2025--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced the completion of the full study that followed the initial Probudur™ pilot study performed by the U.S. Army Institute of Surgical Research (USAISR) under an existing Cooperative Research and

Business Wire 2 months ago

VRPX
-9.93%
Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference

BERWYN, Pa., January 31, 2025--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is pleased to announce its senior director of portfolio management, Matthew Barnes, will be presenting at Outsourcing in Clinical Trial Conference.

Business Wire 3 months ago

VRPX
-9.93%
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals’ $6 Million Follow-On Offering

NEW YORK, NY, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a leading full-service investment banking and financial advisory firm, is proud to announce its role as sole placement agent for Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) in the successful close of its $6 million follow-on offering. Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) is a preclinical-stage pharmaceutical company pioneering novel drug delivery systems for pain management and central nervous system disorder

GlobeNewswire 3 months ago

VRPX
-9.93%
Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants

BERWYN, Pa., January 30, 2025--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the closing of its public offering of $6.0 million of shares of the Company’s common stock, par value $0.00001 per share, and pre-funded warrants to purchase shares of common stock at a public offering price of $0.20 per share (minus $0.00001 per pr

Business Wire 3 months ago

VRPX
-9.93%
Virpax Pharmaceuticals, Inc. Announces Pricing of $6 Million Public Offering of Common Stock and Pre-Funded Warrants

BERWYN, Pa., January 28, 2025--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the pricing of its public offering of $0.20 of shares of the Company’s common stock, par value 0.00001 per share, and/or pre-funded warrants to purchase shares of common stock at a public offering price of $0.19999 per share (minus $0.00001 per pre-

Business Wire 3 months ago

VRPX
-9.93%
Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™

BERWYN, Pa., November 22, 2024--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced results from a minipig Dose Range Finding ("DRF") study for Probudur. Probudur is the company’s long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediat

Business Wire 5 months ago

VRPX
-9.93%
Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative

BERWYN, Pa., November 21, 2024--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a company specializing in developing pharmaceutical products for pain management, announced that it has been granted an extension of its cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), an institute/center of the National Institutes of Health (NIH), U.S. Department of Health and Human Services. This collaboration is for the

Business Wire 5 months ago

VRPX
-9.93%
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering

New York, NY, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a leading investment banking firm, is pleased to announce its role as the sole placement agent in Virpax Pharmaceuticals, Inc.'s (Nasdaq: VRPX) successful $5.0 million public offering of common stock and pre-funded warrants. Virpax Pharmaceuticals, a preclinical-stage pharmaceutical company focused on developing novel and proprietary drug delivery systems across various pain indications, raised $5.0 million through

GlobeNewswire 5 months ago

VRPX
-9.93%
Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants

BERWYN, Pa., November 15, 2024--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the closing of its public offering of $5.0 million of shares of the Company’s common stock, par value $0.00001 per share, and pre-funded warrants to purchase shares of common stock at a public offering price of $0.50 per share (minus $0.00001 per p

Business Wire 5 months ago

VRPX
-9.93%
Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants

BERWYN, Pa., November 13, 2024--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the pricing of its public offering of $5.0 million of shares of the Company’s common stock, par value 0.00001 per share, and/or pre-funded warrants to purchase shares of common stock at a public offering price of $0.50 per share (minus $0.00001 per

Business Wire 5 months ago

VRPX
-9.93%
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Vinay Shah as the Company’s Chief Financial Officer, effective November 16, 2024. Vinay Shah is an accomplished Chief Financial Officer with over 25 years of experience in the pharmaceutical, biophar

GlobeNewswire 5 months ago

ADIL

VRPX
-9.93%
Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments

BERWYN, Pa., August 13, 2024--Virpax Reports 2024 Second Quarter Results and Recent Developments

Business Wire 8 months ago

VRPX
-9.93%
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15

BERWYN, Pa., August 08, 2024--Virpax to Present at Sidoti Virtual Investor Conference August 14-15

Business Wire 8 months ago

VRPX
-9.93%
Virpax Regains Compliance with Nasdaq Minimum Bid Price

BERWYN, Pa., July 24, 2024--Virpax Regains Compliance with Nasdaq Minimum Bid Price

Business Wire 9 months ago

VRPX
-9.93%

Performance Overview

Return	VRPX	S&P 500 (^GSPC)
YTD	-97.44%	-4.26%
1-Year	-99.55%	+8.55%
3-Year	-99.94%	+36.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Virpax Pharmaceuticals, Inc. (VRPX)

Virpax Pharmaceuticals Announces Reverse Stock Split

Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND

Virpax Looking to Use MET to Develop Intranasal COVID Vaccine

Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS

Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology

Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate

Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study

Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference

Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals’ $6 Million Follow-On Offering

Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Virpax Pharmaceuticals, Inc. Announces Pricing of $6 Million Public Offering of Common Stock and Pre-Funded Warrants

Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™

Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering

Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments

Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15

Virpax Regains Compliance with Nasdaq Minimum Bid Price

Performance Overview